



# InterveXion to Present IXT-m200 Program and Phase 2 STAMPOUT Design at College on Problems in Drug Dependence Meeting

*STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users*

LITTLE ROCK, AR, USA, May 23, 2018 /EINPresswire.com/ -- InterveXion Therapeutics, a private clinical-stage biopharmaceutical company, today announced two upcoming presentations on IXT-m200 at the 2018 College on Problems of Drug Dependence in San Diego, California on June 9-14, 2018. IXT-m200, a monoclonal antibody that specifically binds methamphetamine in the blood, is being developed as a pharmacological treatment for use in conjunction with behavioral therapies and is InterveXion's lead program in treating methamphetamine abuse. IXT-m200 is expected to alter methamphetamine pharmacokinetics in human subjects resulting in reduced or blocked subjective effects that reinforce methamphetamine use.

InterveXion will present key program updates on IXT-m200 in the following sessions:

- Ryan Turncliff et al., "Initiation of STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy in Recreational Methamphetamine Abusers", Poster Presentation, June 11, 8:00 PT
- W. Brooks Gentry, "Phase 1 to 2a clinical studies of a monoclonal antibody for treating methamphetamine use disorders", Symposium Session (Chaired by Dr. Ivan Montoya, Deputy Director, Division of Therapeutics and Medical Consequences, NIDA and Dr. S. Michael Owens, Chief Scientific Officer, InterveXion) June 12, 10:00 PT

"We are pleased to have the opportunity to present our program at the College on Problems in Drug Dependence.", noted Dr. W. Brooks Gentry, InterveXion's Chief Medical Officer. "Our recent initiation of the STAMPOUT study highlights our commitment to the development of therapies for patients suffering from substance abuse disorders, and we are looking forward to sharing the details of our program with the scientific community".

STAMPOUT is funded by a three-year \$8 million grant award from the National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA). A sub-award to the University of Arkansas for Medical Sciences (UAMS) is part of the grant and funds researchers who are both founders of the company and also prominent UAMS leaders. InterveXion is a BioVentures, LLC, client company housed on the UAMS campus in Little Rock, AR.

For more information on InterveXion, visit: <https://www.intervexion.com>.

InterveXion is a biopharmaceutical company whose mission is to discover and advance innovative medications that reduce the impact of human suffering on individuals and communities. Its vision is to be a leader in the development of antagonist therapies that neutralize toxins in the body and thereby improve patient health. InterveXion's first medications are a monoclonal antibody and an active vaccine for treating methamphetamine abuse. For more information, contact [intervexion@gmail.com](mailto:intervexion@gmail.com).

STAMPOUT is supported by NIH/NIDA under Award Number U01DA045366. The content of this release is solely the responsibility of InterveXion and does not necessarily represent the official views of the National Institutes of Health.

Misty Stevens  
InterveXion Therapeutics  
501-554-2377  
[email us here](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.